Welcome to our dedicated page for Cooper news (Ticker: COO), a resource for investors and traders seeking the latest updates and insights on Cooper stock.
The Cooper Companies, Inc. reports developments for a global medical device business organized around CooperVision and CooperSurgical. CooperVision news centers on soft contact lenses, specialty lens designs, myopia management products such as MiSight® 1 day, MyDay® contact lenses, practitioner support, and sustainability initiatives tied to lens materials, packaging, manufacturing, and plastic footprint programs.
CooperCompanies news also covers quarterly financial results, conference participation, board appointments, and governance matters. CooperSurgical provides fertility and women’s healthcare products, while companywide updates describe operating performance, capital priorities, and corporate developments across its medical device portfolio.
CooperCompanies (NYSE: COO) announced that it will release its fourth quarter and full year 2020 financial results on December 3, 2020, at 4:15 PM ET. A conference call will follow at 5:00 PM ET to discuss these results and current developments. Participants can join via a dedicated dial-in number or through a live webcast on the CooperCompanies investor relations website. A recording of the call will be available until December 10, 2020. CooperCompanies operates two units: CooperVision and CooperSurgical, focusing on vision care and women's health, respectively.
CooperSurgical and NYU Langone Fertility Center's recent study has shown that the PGTai 2.0 technology significantly enhances ongoing pregnancy and live birth rates in IVF procedures. Presented at the ASRM Annual Meeting, the study analyzed over 700 patients and found a 13% relative increase in successful outcomes compared to earlier methods. This advancement utilizes artificial intelligence for improved embryo assessment, aligning with the company's goal of optimizing reproductive success.
CooperVision reported findings from its six-year MiSight® 1 day clinical study, revealing that 23% of children's eyes remained stable for myopia. The study highlighted the lens's efficacy in myopia management, demonstrating a continued excellent safety profile and visual acuity over 653 wearing years. Although early intervention is ideal, initiating treatment later can still effectively slow myopia progression. CooperVision's MiSight® is the only FDA-approved lens for this purpose in children aged 8-12, forming the core of its Brilliant Futures™ program, recently expanded to several countries.
Summary not available.
CooperCompanies (NYSE: COO) reported a 15% decline in fiscal Q3 revenue to $578.2 million, with CooperVision and CooperSurgical revenues falling 12% and 24%, respectively. GAAP diluted EPS was $1.12, down 53% year-over-year, while non-GAAP diluted EPS decreased 30% to $2.28. Despite COVID-19 challenges, the company noted a faster-than-anticipated recovery and provided Q4 revenue guidance of $665-$693 million. Operating and gross margins also saw reductions, attributed to heightened COVID-related expenses. The debt at the end of the quarter stood at $1.88 billion, with cash equivalents of $127.4 million.
CooperCompanies (NYSE: COO) will participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 23, 2020, at 3:20 pm ET. Senior Vice President and CFO Brian Andrews will represent the company in a virtual session. Investors can access the session via a webcast available on the Investor Relations section of Cooper's website. CooperCompanies operates through two main units: CooperVision, focusing on vision care, and CooperSurgical, dedicated to women's health and fertility. The company has over 12,000 employees globally.
CooperVision has announced Sarah Michelle Gellar as the spokesperson for its Brilliant Futures™ Myopia Management Program, aimed at increasing awareness of myopia among children. The program features the MiSight® 1 day lens, FDA-approved to slow myopia progression in children aged 8-12. With myopia affecting over 40% of Americans, CooperVision emphasizes the importance of early intervention during a time of increased screen usage.
The campaign includes national advertising and collaboration with the National Association of School Nurses to educate parents about myopia management.
CooperCompanies (NYSE: COO) will participate in the Morgan Stanley Virtual 18th Annual Global Healthcare Conference on September 16, 2020, with Senior VP and CFO Brian Andrews leading the presentation starting at 2:45 pm ET. Interested investors can access the session via a webcast on Cooper's Investor Relations website.
Cooper operates globally with two main units: CooperVision, focusing on vision care products, and CooperSurgical, dedicated to women's health and fertility solutions. The company has over 12,000 employees and products available in more than 100 countries.
CooperCompanies (NYSE: COO) will participate in the 2020 Wells Fargo Virtual Healthcare Conference on September 10, 2020, at 1:20 pm ET. CEO Al White will represent the company during this session. A webcast of the presentation will be available on the Investor Relations section of Cooper's website, ensuring accessibility for stakeholders and investors. CooperCompanies is a global medical device firm operating through CooperVision and CooperSurgical, focusing on vision care and women's health products with a workforce exceeding 12,000 across more than 100 countries.
CooperCompanies (NYSE: COO) will announce its third quarter 2020 financial results on September 3, 2020, at 4:15 PM ET. Following the release, a conference call will take place at 5:00 PM ET to discuss these results and other corporate developments. Interested participants can join the call by dialing 855-643-4430 (U.S.) or 707-294-1332 (International) with the passcode 'Cooper'. A simultaneous webcast will be available on the company's website, and a recording will be accessible from September 3 through September 10, 2020.